Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | GRM8 | O00222 | 1/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | GLUL | P15104 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoramidic Acid SCHEMBL13280710 | 1.00 | FOLH1 (0.34) | FOLH1GRM8GRM6GRM7GRM4 | |
| SCHEMBL1890693 | 0.98 | FOLH1 (0.35) | FOLH1GRM8GRM6GRM7GRM4 | |
| SCHEMBL4297049 | 0.84 | CA4 (0.39) | FOLH1GRM8GRM6GRM7GRM4 | |
| SCHEMBL771739 | 0.84 | CA4 (0.39) | FOLH1GRM8GRM6GRM7GRM4 | |
| SCHEMBL771738 | 0.84 | CA4 (0.39) | FOLH1GRM8GRM6GRM7GRM4 | |
| SCHEMBL1890700 | 0.84 | FOLH1 (0.32) | FOLH1GRM8GRM6GRM7GRM4 | |
| SCHEMBL28006119 | 0.82 | CA4 (0.38) | FOLH1GRM8GRM6GRM7GRM4 | |
| SCHEMBL1890691 | 0.82 | CYP2D6 (0.31) | — | |
| Aspartic Acid SCHEMBL4775933 | 0.79 | GRM8 (0.40) | FOLH1GRM8GRM6GRM7GRM4 | |
| SCHEMBL28278353 | 0.79 | CA4 (0.40) | FOLH1GRM8GRM6GRM7GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012158197-A2 | COMPOUNDS USEFUL AS AKT/PKB MODULATORS AND USES THEREOF | LYNDOR BIOSCIENCES L.L.C. (US) | 2012-11-22 | — | — | WO | claimed |
| WO-2012142388-A2 | METHODS, COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING ANXIETY AND MOOD DISORDERS | NEW YORK UNIVERSITY (US) | 2012-10-18 | — | — | WO | claimed |
| US-20120010125-A1 | Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders | STONE ERIC A (US) | 2012-01-12 | — | — | US | claimed |
| WO-2011133212-A1 | METHODS, COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING ANXIETY AND MOOD DISORDERS | NEW YORK UNIVERSITY (US) | 2011-10-27 | — | — | WO | claimed |
| US-20100093609-A1 | PRODRUGS OF TRICIRIBINE AND TRICIRIBINE PHOSPHATE | TSRL, INC. | 2010-04-15 | — | — | US | claimed |
| WO-2008121941-A1 | PRODRUGS OF TRICIRIBINE AND TRICIRIBINE PHOSPHATE | TSRL, INC. (US) | 2008-10-09 | — | — | WO | claimed |
| US-9265774-B2 | Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders | NEW YORK UNIVERSITY (US) | 2016-02-23 | — | — | US | disclosed |
| US-9023788-B2 | Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders | NEW YORK UNIVERSITY (US) | 2015-05-05 | — | — | US | disclosed |
| WO-2012158197-A2 | COMPOUNDS USEFUL AS AKT/PKB MODULATORS AND USES THEREOF | LYNDOR BIOSCIENCES L.L.C. (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120010125-A1 | Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders | STONE ERIC A (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2011133212-A1 | METHODS, COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING ANXIETY AND MOOD DISORDERS | NEW YORK UNIVERSITY (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20100093609-A1 | PRODRUGS OF TRICIRIBINE AND TRICIRIBINE PHOSPHATE | TSRL, INC. | 2010-04-15 | — | — | US | disclosed |
| WO-2008121941-A1 | PRODRUGS OF TRICIRIBINE AND TRICIRIBINE PHOSPHATE | TSRL, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010125-A1 | Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders | HTR1B, HTR1A, HTR2B | FOLH1 4455/4885GRM8 289/4885GRM6 125/4885 |
| US-20100093609-A1 | PRODRUGS OF TRICIRIBINE AND TRICIRIBINE PHOSPHATE | TYMP, SLC1A5, TYMS | FOLH1 123/4885GRM8 3041/4885GRM6 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.